Rapport Therapeutics CEO sells 2,210 shares under plan
Rhea-AI Filing Summary
Rapport Therapeutics, Inc. Chief Executive Officer Abraham Ceesay reported selling a total of 2,210 shares of common stock on July 27, 2026, in two transactions, including 2,203 shares at a weighted average price of $42.1070 (with individual trades between $41.66 and $42.50) and 7 shares at $42.7350 per share, pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.
Separate from these sales, 81,729 shares are held by The Ceesay Family Irrevocable Trust and 20,729 shares by The Dorothy Ceesay Irrevocable Trust; Ceesay disclaims beneficial ownership of these trust-held shares except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 2,210 shares
Net Sell
4 txns
Insider
Ceesay Abraham
Role
Chief Executive Officer
Sold
2,210 shs ($93K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 2,203 | $42.107 | $93K |
| Sale | Common Stock F1 | 7 | $42.735 | $299.15 |
| holding | Common Stock F3 | -- | -- | -- |
| holding | Common Stock F4 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 537,607 shares (Direct);
Common Stock — 81,729 shares (Indirect, By Ceesay Family Irrevocable Trust);
Common Stock — 20,729 shares (Indirect, By Dorothy Ceesay Irrevocable Trust)
Footnotes (4)
- F1. These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.66 to $42.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- F4. Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Key Figures
Shares sold: 2,203 shares
Additional shares sold: 7 shares
Weighted average sale price: $42.1070 per share
+4 more
7 metrics
Shares sold
2,203 shares
Common stock sold on July 27, 2026 at a weighted average price
Additional shares sold
7 shares
Common stock sold on July 27, 2026 at $42.7350 per share
Weighted average sale price
$42.1070 per share
Average price for the 2,203-share common stock sale on July 27, 2026
Sale price range
$41.66–$42.50 per share
Range of individual trade prices within the 2,203-share transaction
Ceesay Family Trust holdings
81,729 shares
Common stock held by The Ceesay Family Irrevocable Trust as of July 27, 2026
Dorothy Ceesay Trust holdings
20,729 shares
Common stock held by The Dorothy Ceesay Irrevocable Trust as of July 27, 2026
Rule 10b5-1 plan adoption date
March 27, 2026
Date the CEO’s trading plans governing these sales were adopted
Key Terms
Rule 10b5-1 trading plans, weighted average price, pecuniary interest, beneficial ownership, +1 more
5 terms
Rule 10b5-1 trading plans regulatory
"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans."
Rule 10b5-1 trading plans are written, pre-arranged instructions that allow company insiders (such as executives or directors) to automatically buy or sell their company's stock at specified times or under set conditions, like a standing instruction or automated thermostat for trades. They matter to investors because these plans provide a legal defense against insider‑trading accusations and create predictable insider trading patterns that can help signal whether sales are routine portfolio management or potentially meaningful to the company’s outlook.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
pecuniary interest financial
"except to the extent of his pecuniary interest therein, if any."
beneficial ownership regulatory
"The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 of the Securities Exchange Act of 1934 regulatory
"for purposes of Section 16 of the Securities Exchange Act of 1934, as amended."
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Were Abraham Ceesay’s RAPP stock sales made under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. Such pre-arranged plans allow trades to occur under preset instructions.
What role does Abraham Ceesay hold at Rapport Therapeutics (RAPP)?
Abraham Ceesay is reported as the Chief Executive Officer and an officer and director of Rapport Therapeutics, Inc. His Form 4 filing covers personal and related trust holdings in the company’s common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
